Octoplus« Terug naar discussie overzicht

1. flosz 5 februari 2012 11:31

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   quote:

   + schreef op 4 februari 2012 20:25:

   Las laatst een keer(kan het niet vinden ) dat Biolex krap bij kas zat.
   Nu hebben ze een paar weken terug geld opgehaald t.b.v. SEC-Filling.
   Investeerders geven/gaven 10milj. Doe er wat mee dan!!! www.biolex.com/products-.htm
   
   apps.firstrain.com/SeekingAlpha/001/d...
   

   Krap bij kas zit Biolex imho nog steeds.
   10 mil. tbv de toezichthouder, amai…..
   5.9 van een paar weken terug is iets langer geleden(06-2011) en van de aangeboden 3.2 is 2.4 "verpatst".
   
   www.sec.gov/cgi-bin/browse-edgar?acti...
   www.sec.gov/answers/rule506.htm
   Clarus Ventures-backed Biolex Therapeutics Raises 75% of $3.2M Offering
   Biolex Therapeutics Inc. has raised $2.4 million, or 75 percent of a $3.2 million debt offering, from 10 investors, according to an SEC filing.
   
   Principals named in the filing by the Pittsboro, N.C.-based drug developer are:
   
   • Chairman P. Sheriff Neff;
   • Executive Chairman Kurt Graves;
   • President and CEO Jan Turek;
   • COO David Spencer;
   • CFO Dale Sander;
   • Director Dennis Dougherty of Durham, N.C.-based Intersouth Partners;
   • Director W. Amick, an advisor to Intersouth Partners and Philadelphia-based Quaker BioVentures;
   • Jeffrey Leiden of Cambridge, Mass.-based Clarus Ventures;
   • Director David Castaldi, an entrepreneur and former president of Baxter International; and
   • Liza Nelson of Sweden's Investor Growth Capital with offices in New York.
   In June, the company raised $5.9 million through a sale of debt and convertible securities.
   
   Biolex Therapeutics is a clinical-stage biopharmaceutical company that uses its patented LEX System to develop follow-on biologics, hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a novel technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates.